Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked conscientiously but unsuccessfully to create an one off therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past several shares of mine. My first CytoDyn post, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set out all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire employment interview that I came away with a bad impression of the company.

Irony of irony, my bad opinion of the company has grown steadily, although the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of this know-how as well as linked intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) along with the very first new drug program endorsement ($5 million), as well as royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and multiple therapies, it’s this single treatments and a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several disease sorts, multiple presentations in addition to multiple publications.

Might all this be smoke and mirrors? That’s a question I have been asking myself with the very beginning of my interest in this particular company. Judging by the multiples of thousands of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this question.

CytoDyn is a traditional battleground, or some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *